Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 5/20 | 0.75 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | CXCR6 | O00574 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | ALPL | P05186 | 1/20 | 0.37 |
| ▸ | ALPI | P09923 | 1/20 | 0.37 |
| ▸ | ALPG | P10696 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | FPR1 | P21462 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5870843 | 1.00 | CCR3 (0.75) | CCR3FPR2CXCR6TP53ALPL | |
| SCHEMBL5870847 | 1.00 | CCR3 (0.75) | CCR3FPR2CXCR6TP53ALPL | |
| SCHEMBL27641294 | 1.00 | CCR3 (0.75) | CCR3FPR2CXCR6TP53ALPL | |
| SCHEMBL5870716 | 0.91 | CCR3 (0.76) | CCR3FPR2CXCR6TP53ALPL | |
| SCHEMBL5870672 | 0.85 | CCR3 (0.56) | CCR3FPR2CXCR6TP53ALPL | |
| SCHEMBL5870723 | 0.81 | CCR3 (0.76) | CCR3FPR2MEN1KMT2A | |
| SCHEMBL1224281 | 0.77 | CCR3 (1.00) | CCR3FPR2CXCR6TP53ALPL | |
| SCHEMBL1223391 | 0.74 | CCR3 (0.77) | CCR3TP53ALPLALPIALPG | |
| SCHEMBL1223389 | 0.74 | CCR3 (0.77) | CCR3TP53ALPLALPIALPG | |
| SCHEMBL1223394 | 0.74 | CCR3 (0.77) | CCR3TP53ALPLALPIALPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060194790-A1 | Bridged bicyclic amine derivatives useful as CCR-3 receptor antagonists | GONG LEYI | 2006-08-31 | — | — | US | disclosed |
| US-20060189596-A1 | Bridged bicyclic amine derivatives useful as CCR-3 receptor antagonists | GONG LEYI | 2006-08-24 | — | — | US | disclosed |
| US-7081531-B2 | Bridged bicyclic amine derivatives useful as CCR-3 receptor antagonists | ROCHE PALO ALTO LLC (US) | 2006-07-25 | — | — | US | disclosed |
| CN-1753891-A | Ccr-3 receptor antagonists | HOFFMANN LA ROCHE (CH) | 2006-03-29 | — | — | CN | disclosed |
| US-20040176416-A1 | Bridged bicyclic amine derivatives useful as CCR-3 receptor antagonists | ROCHE PALO ALTO LLC | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189596-A1 | Bridged bicyclic amine derivatives useful as CCR-3 receptor antagonists | CCR3, CCR10, CCR1 | CCR3 1/4885FPR2 216/4885CXCR6 211/4885 |
| US-20040176416-A1 | Bridged bicyclic amine derivatives useful as CCR-3 receptor antagonists | CCR3, CCR1, CCR10 | CCR3 1/4885FPR2 272/4885CXCR6 200/4885 |
| US-20060194790-A1 | Bridged bicyclic amine derivatives useful as CCR-3 receptor antagonists | CCR3, CCR10, CCR1 | CCR3 1/4885FPR2 172/4885CXCR6 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.